ADMA Biologics, Inc. Provides Earnings Guidance for the Fiscal Year 2022 and 2024
August 11, 2022 at 01:35 am IST
Share
ADMA Biologics, Inc. provided earnings guidance for the fiscal year 2022 and 2024. For the year 2022, the company expects total revenues will exceed $130 million.
For the year 2024, the company expects $250 million or more in topline revenue in 2024, net income in the range of $50 million - $100 million during the 2024-2025 time period and beyond.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.